Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Badesch

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Journal of the American College of Cardiology|April 25, 2009
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationVallerie V McLaughlin, Stephen L Archer, David B Badesch, et al.
JACC. Heart Failure|July 15, 2023
Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR StudyMardi Gomberg-Maitland, Vallerie V McLaughlin, David B Badesch, et al.
The European Respiratory Journal|April 4, 2015
Validation of two predictive models for survival in pulmonary arterial hypertensionOlivier Sitbon, Raymond L Benza, David B Badesch, et al.
Chest|April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY TrialKelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.
Chest|October 20, 2009
Pulmonary arterial hypertension: baseline characteristics from the REVEAL RegistryDavid B Badesch, Gary E Raskob, C Greg Elliott, et al.
Chest|August 29, 2020
United States Pulmonary Hypertension Scientific Registry: Baseline CharacteristicsJessica B Badlam, David B Badesch, Eric D Austin, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2009
Genetic risk factors for portopulmonary hypertension in patients with advanced liver diseaseKari E Roberts, Michael B Fallon, Michael J Krowka, et al.
Chest|May 28, 2026
Sotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLARMardi Gomberg-Maitland, H Ardeschir Ghofrani, J Simon R Gibbs, et al.
Journal of Cardiovascular Pharmacology|January 28, 2003
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertensionVallerie V McLaughlin, Sean P Gaine, Robyn J Barst, et al.
The New England Journal of Medicine|March 31, 2021
Sotatercept for the Treatment of Pulmonary Arterial HypertensionMarc Humbert, Vallerie McLaughlin, J Simon R Gibbs, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Journal of the American College of Cardiology|April 25, 2009
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationVallerie V McLaughlin, Stephen L Archer, David B Badesch, et al.
JACC. Heart Failure|July 15, 2023
Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR StudyMardi Gomberg-Maitland, Vallerie V McLaughlin, David B Badesch, et al.
The European Respiratory Journal|April 4, 2015
Validation of two predictive models for survival in pulmonary arterial hypertensionOlivier Sitbon, Raymond L Benza, David B Badesch, et al.
Chest|April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY TrialKelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.
Chest|October 20, 2009
Pulmonary arterial hypertension: baseline characteristics from the REVEAL RegistryDavid B Badesch, Gary E Raskob, C Greg Elliott, et al.
Chest|August 29, 2020
United States Pulmonary Hypertension Scientific Registry: Baseline CharacteristicsJessica B Badlam, David B Badesch, Eric D Austin, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2009
Genetic risk factors for portopulmonary hypertension in patients with advanced liver diseaseKari E Roberts, Michael B Fallon, Michael J Krowka, et al.
Chest|May 28, 2026
Sotatercept Safety and Efficacy in Intermediate-Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLARMardi Gomberg-Maitland, H Ardeschir Ghofrani, J Simon R Gibbs, et al.
Journal of Cardiovascular Pharmacology|January 28, 2003
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertensionVallerie V McLaughlin, Sean P Gaine, Robyn J Barst, et al.
The New England Journal of Medicine|March 31, 2021
Sotatercept for the Treatment of Pulmonary Arterial HypertensionMarc Humbert, Vallerie McLaughlin, J Simon R Gibbs, et al.
Pageof 9